Hassandavidsen8710

To compare conventional sensitivity encoding turbo spin-echo (SENSE-TSE) with compressed sensing plus SENSE turbo spin-echo (CS-TSE) in lumbar vertebrae magnetic resonance imaging (MRI).

This retrospective study of lumbar vertebrae MRI included 600 patients; 300 patients received SENSE-TSE and 300 patients received CS-TSE. The SENSE acceleration factor was 1.4 for T1WI, 1.7 for T2WI, and 1.7 for PDWI. The CS total acceleration factor was 2.4, 3.6, 4.0, and 4.0 for T1WI, T2WI, PDWI sagittal, and T2WI transverse, respectively. The image quality of each MRI sequence was evaluated objectively by the signal-to-noise ratio (SNR) and contrast-to-noise ratio (CNR) and subjectively on a five-point scale. Two radiologists independently reviewed the MRI sequences of the 300 patients receiving CS-TSE, and their diagnostic consistency was evaluated. The degree of intervertebral foraminal stenosis and nerve root compression was assessed using the T1WI sagittal and T2WI transverse images.

The scan time was reduced from 7 min 28 s to 4 min 26 s with CSTSE. The median score of nerve root image quality was 5 (p > 0.05). The diagnostic consistency using CS-TSE images between the two radiologists was high for diagnosing lumbar diseases (κ > 0.75) and for evaluating the degree of lumbar foraminal stenosis and nerve root compression (κ = 0.882). No differences between SENSE-TSE and CS-TSE were observed for sensitivity, specificity, positive predictive value, or negative predictive value.

CS-TSE has potential for diagnosing lumbar vertebrae and disc disorders.

CS-TSE has potential for diagnosing lumbar vertebrae and disc disorders.Bone disease is the hallmark of multiple myeloma. Skeletal lesions are evaluated to establish the diagnosis, to choose the therapies and also to assess the response to treatments. Due to this, imaging procedures play a key-role in the management of multiple myeloma. For decades, conventional radiography has been the standard imaging modality. Subsequently, advances in the treatment of multiple myeloma have increased the need for accurate evaluation of skeletal disease. The introduction of new high performant imaging tools, such as whole-body low dose computed tomography, different types of magnetic resonance imaging studies, and 18F-fluorodeoxyglucose positron emission tomography, replaced conventional radiography. In this review we analyze the diagnostic potentials, indications of use, and applications of the imaging tools nowadays available. Whole body low-dose CT should be considered as the imaging modality of choice for the initial assessment of multiple myeloma lytic bone lesions. MRI is the gold-standard for detection of bone marrow involvement, while PET/CT is the preferred technique in assessment of response to therapy. Both MRI and PET/CT are able to provide prognostic information.

Cardiovascular disease (CVD) is one of the primary diseases that cause death every year. An approximation of roughly about 17.5 million people dies due to CVD, signifying about 31% of global deaths. Based on the statistics, for every 34 seconds the people were died due to heart disease. Pracinostat mouse Various classification algorithms have been developed and utilized as classifiers to support doctors who are ineffectually diagnosed with heart disease.

The main aim of this work is to improve the performance of heart disease approach using image processing algorithm. To improve the effectiveness and efficiency of classification performance for heart disease diagnosis, an optimized neural network was proposed based on the feature extraction and selection approach for handling features.

The objective of this investigation is to diagnosis heart disease using feature extraction and reduction based classification using image processing methods. The proposed model comprises of two subsets Feature extraction using gray scale peature extraction based classification or the feature reduction based classification.

In this, the feature extraction using the gray scale properties plays an important role to determine the feature attributes from the MRI heart images. The Moth flame optimization able to produce an accuracy of 97.23% using GRNN for classification with minimum single attribute mean of the image. It also outperformed the other methods either the feature extraction based classification or the feature reduction based classification.

The optimal duration of dual antiplatelet therapy is a matter of ongoing research. Clinical studies are assessing the optimal duration with the most favourable risk to benefit ratio. The efficacy of P2Y12 receptor inhibitors has been shown comparable to aspirin in preventing recurrent ischaemic events in patients with coronary artery diseases.

To investigate the outcomes of short-duration dual antiplatelet therapy after PCI with early discontinuation of aspirin while maintaining patients on P2Y12 inhibitor through systematic review and meta-analysis of available literature.

We systematically searched Pubmed, Cochrane Central Register of Controlled Trials (CENTRAL) and ClinicalTrials.gov. We included randomised controlled studies that measured clinical outcomes of efficacy (mortality and ischaemic events) and safety (bleeding) of short and standard duration dual antiplatelet therapy. The protocol of this study was registered in the International prospective register of systematic reviews PROSPERO registry (CRD42020171468).

Four randomised controlled trials were included; GLOBAL LEADERS, SMART-CHOICE, STOPDAPT-2 and TWILIGHT. The total number of patients was 29,089. The safety outcomes showed a significant reduction in major bleeding events with short-duration dual antiplatelet therapy; risk ratio is 0.61 (95% CI 0.38-0.99; z=2,00, p=0.05). There was no difference between short and standard duration dual antiplatelet therapy regarding efficacy outcomes (all-cause death, major adverse cardiovascular events, myocardial infarction, stroke and stent thrombosis).

Short-duration dual antiplatelet therapy followed by P2Y12 inhibitor monotherapy after PCI is a feasible option and can be adopted, especially in patients with a high risk of bleeding.

Short-duration dual antiplatelet therapy followed by P2Y12 inhibitor monotherapy after PCI is a feasible option and can be adopted, especially in patients with a high risk of bleeding.